Patents by Inventor Patrick Larpent

Patrick Larpent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREPARING ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF
    Publication number: 20260193350
    Abstract: The invention provides methods for producing high concentration crystalline drug substances of an anti-PD-1 mono-clonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant. The invention further relates to pharmaceutical compositions comprising the crystals produced by the methods herein and methods of use thereof.
    Type: Application
    Filed: November 20, 2023
    Publication date: July 9, 2026
    Applicants: Merck Sharp & Dohme LLC, Werthenstein Biopharma GmbH
    Inventors: Paul Reichert, Chakravarthy Nachu Narasimhan, Andrew Bochnovich, Divya Chandra, Rebecca A. Chmielowski, Lorenzo Codan, Aaron S. Cote, Ashley E. Lay-Fortenbery, Patrick Larpent, Zhao Li, Mikhail D. Murashov, Jordan R. Rampolla, Yongchao Su
  • PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS
    Publication number: 20260062394
    Abstract: The invention relates to crystalline forms and processes for preparing a compound of Formula I (I) and pharmaceutically acceptable salts thereof which are useful for the treatment of bacterial infections, particularly mycobacterial infections. The invention also relates to intermediates used in the processes for preparing the compound of Formula I for the treatment of mycobacterial infections such as those caused by Mycobacteria tuberculosis.
    Type: Application
    Filed: August 7, 2023
    Publication date: March 5, 2026
    Applicants: Merck Sharp & Dohme LLC, Werthenstein BioPharma GmbH
    Inventors: David Harris, Patrick Larpent, Zhao Liu, Ashish Punia, Wes A. Schafer, Lushi Tan, Yingju Xu, Chintal Desai
  • CRYSTALLINE FORMS OF A PCSK9 INHIBITOR, COMPOSITIONS AND USES
    Publication number: 20260035411
    Abstract: This disclosure provides crystalline forms of a compound of Formula (I), as well as pharmaceutically acceptable compositions thereof, and methods for their preparation and use in methods of treating hypercholesterolemia and other conditions related to PCSK9 activity, e.g., atherosclerosis, atherosclerotic cardiovascular disease, peripheral arterial disease, cerebrovascular disease, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Application
    Filed: August 16, 2023
    Publication date: February 5, 2026
    Inventors: Jongrock KONG, Richard J. VARSOLONA, Richard DESMOND, Peter E. MALIGRES, Fuh-Rong TSAY, Carlos Alberto Pons SIEPERMANN, Artis KLAPARS, Lee ROBISON, Alfred LEE, Tiffany PIOU, Lorenzo CODAN, Patrick LARPENT
  • Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
    Patent number: 11827614
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignees: Merck Sharp & Dohme LLC, Werthenstein Biopharma GMBH
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
  • PROCESS FOR PREPARING SUGAMMADEX
    Publication number: 20230312887
    Abstract: The present invention relates to a process for drying crystalline sugammadex to meet solvent specifications that is independent of API crystallinity or crystalline form generated. It further relates to use of sugammadex in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 5, 2023
    Applicants: Merck Sharp & Dohme LLC, Werthenstein BioPharma GMBH
    Inventors: David J. Lamberto, Paolo Avalle, Lorenzo Codan, Patrick Larpent, Jochen Schoell, Jeffrey S. Neuhaus
  • NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES
    Publication number: 20220388974
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 8, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
  • NOVEL CRYSTALLINE FORMS OF SUGAMMADEX
    Publication number: 20220049023
    Abstract: The present invention provides a novel crystalline forms of sugammadex, designated herein as crystalline form Type 1 of sugammadex, crystalline form Type 2 of sugammadex, crystalline form Type 3 of sugammadex, crystalline form Type 8 of sugammadex, and crystalline form Type 9 of sugammadex, pharmaceutical compositions thereof, and methods for their use in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 17, 2022
    Applicant: Werthenstein Biopharma GMBH
    Inventors: Paolo Avalle, Lorenzo Codan, Patrick Larpent, Jochen Scholl
  • NOVEL PROCESS FOR SYNTHESIS OF A PHENOXY DIAMINOPYRIMIDINE COMPOUND
    Publication number: 20210122717
    Abstract: Disclosed herein is a novel process for preparing Compound A free base, 5-((2,4-diaminopyrimidin-5-yl)oxy)-4-iso-propyl-2-methoxybenzenesulfonamide, and a citrate salt of Compound A with simplified chemistry and a high overall yield: Compound A. In one embodiment, the overall yield from the starting material 2-isopropylphenol to Compound A citrate salt is greater than 50%. In another embodiment, the overall yield is greater than 60%. Also disclosed herein are novel salts and solvates of Compound A.
    Type: Application
    Filed: April 18, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Werthenstein BioPharma GmbH
    Inventors: Kevin M. Maloney, Kallol Basu, John Y.L. Chung, Richard Desmond, Michael James Di Maso, Guy R. Humphrey, Alfred Y. Lee, Dan Lehnherr, Feng Peng, Hong Ren, Mark Weisel, Siwei Zhang, Patrick Larpent